Lyell Immunopharma, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2021 | $-33.6M | $-52.8M | $19.2M | $12.7M |
| Mar 2022 | $-47.9M | $-57.6M | $9.7M | $22.0M |
| Mar 2023 | $-46.2M | $-47.7M | $1.5M | $13.9M |
| Mar 2024 | $-42.0M | $-42.0M | $30.0K | $9.2M |
| Mar 2025 | $-54.7M | $-55.0M | $246.0K | $6.0M |
| Mar 2026 | $-38.5M | $-38.6M | $89.0K | $4.3M |